NCT05719805View on ClinicalTrials.gov

A Study to Evaluate the Effects of Mavacamten in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

February 20, 2023

Primary Completion Date

July 25, 2023

Study Completion Date

July 25, 2023

Conditions
Healthy Participants
Interventions
DRUG

Mavacamten

Specified dose on specified days

Trial Locations (2)

33136

Local Institution - 0001, Miami

55114

Local Institution - 0002, Saint Paul

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05719805 - A Study to Evaluate the Effects of Mavacamten in Healthy Participants | Biotech Hunter | Biotech Hunter